Literature DB >> 1912978

Haemodynamic changes and acetylcholine-induced hypotensive responses after NG-nitro-L-arginine methyl ester in rats and cats.

E Marcel van Gelderen1, J P Heiligers, P R Saxena.   

Abstract

1. The haemodynamic effects of NG-nitro-L-arginine methylester (L-NAME; 1, 3, 10 and 30 mg kg-1) and its potential ability to attenuate the hypotensive responses to acetylcholine (0.03, 0.1, 1.0 and 3.0 micrograms kg-1) have been investigated in anaesthetized rats and cats. 2. In the rat, L-NAME elicited a dose-dependent pressor effect increasing mean arterial blood pressure from the baseline value of 116 +/- 4 mmHg to a maximum of 156 +/- 6 mmHg with 30 mg kg-1. This increase in blood pressure could be only partly reversed by L-arginine (300 mg kg-1). However, the increase in blood pressure by lower doses (up to 10 mg kg-1) of L-NAME was effectively reversed by L-arginine (1000 mg kg-1). 3. In the cat, L-NAME did not significantly modify systemic haemodynamic variables (heart rate, mean arterial blood pressure, cardiac output, stroke volume or total peripheral resistance), when compared to the changes in saline-treated animals. Administration of L-arginine did not cause any significant effect in cats treated with L-NAME, but some decrease in heart rate and increases in cardiac output and stroke volume were observed in the saline-treated group. 4. With the lowest dose (1 mg kg-1), L-NAME did not affect tissue blood flows in the cat, but higher doses (3 and 30 mg kg-1) significantly reduced blood flows to the mesentery, stomach, spleen, intestines, lungs and the total liver. L-Arginine (300mgkg-1) injected into the control (saline-treated) animals resulted in a significant increase in blood flow to the heart, mesentery, lungs as well as the total liver, particularly its portal fraction. L-Arginine-induced increases in tissue blood flows (mesentery, kidneys, spleen, lungs, total liver and portal blood flow) in saline-treated animals were attenuated in animals treated with L-NAME.5. The acetylcholine-induced peak hypotensive response was not reduced in rats or cats by L-NAME. The duration of acetylcholine response was, however, attenuated in both species by L-NAME. Treatment with L-arginine (10-100mg kg- 1) did not change the acetylcholine-induced hypotension.6. The above results reveal a marked difference between the haemodynamic effects of L-NAME in rats and cats and suggest that in cats, unlike rats, the role of the L-arginine-NO pathway in the regulation of blood pressure is rather limited, although such a pathway may exist in several tissues. Furthermore, the hypotensive response to acetylcholine in both species seems to be mediated largely by NO-independent pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912978      PMCID: PMC1908207          DOI: 10.1111/j.1476-5381.1991.tb12349.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Blood flow measurements with radionuclide-labeled particles.

Authors:  M A Heymann; B D Payne; J I Hoffman; A M Rudolph
Journal:  Prog Cardiovasc Dis       Date:  1977 Jul-Aug       Impact factor: 8.194

3.  L-arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo.

Authors:  K Aisaka; S S Gross; O W Griffith; R Levi
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

4.  Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation.

Authors:  B J Whittle; J Lopez-Belmonte; D D Rees
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

5.  Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide.

Authors:  C Boulanger; V B Schini; S Moncada; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

6.  Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

7.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

8.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

9.  Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Cardiovasc Res       Date:  1989-12       Impact factor: 10.787

10.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

View more
  12 in total

1.  Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation.

Authors:  Marcelo G Bonini; Krisztian Stadler; Sueli de Oliveira Silva; Jean Corbett; Michael Dore; John Petranka; Denise C Fernandes; Leonardo Y Tanaka; Danielle Duma; Francisco R M Laurindo; Ronald P Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

2.  The role of nitric oxide in the regional vasodilator effects of endothelin-1 in the rat.

Authors:  J R Fozard; M L Part
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

3.  Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.

Authors:  J G Filep; E Földes-Filep; A Rousseau; P Sirois; A Fournier
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Cardiovascular effects of SCA40, a novel potassium channel opener, in rats.

Authors:  A Michel; F Laurent; J Bompart; K Hadj-Kaddour; J P Chapat; M Boucard; P A Bonnet
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

5.  The effects of N omega-nitro-L-arginine methyl ester, sodium nitroprusside and noradrenaline on venous return in the anaesthetized cat.

Authors:  E A Bower; A C Law
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

6.  Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat.

Authors:  J G Filep; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  NG-nitro L-arginine methyl ester: systemic and pulmonary haemodynamics, tissue blood flow and arteriovenous shunting in the pig.

Authors:  E M van Gelderen; M O Den Boer; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

8.  Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide.

Authors:  Michael A Insko; Thomas L Deckwerth; Paul Hill; Christopher F Toombs; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-05-07       Impact factor: 8.739

9.  Inhibition of nitric oxide biosynthesis and carotid arteriovenous anastomotic shunting in the pig.

Authors:  E M van Gelderen; P R Saxena
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats.

Authors:  S M Gardiner; T Rakhit; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.